TrialBone research2026

A phase 2 trial of burosumab for treatment of fibroblast growth factor-23-mediated hypophosphatemia in children and adults with fibrous dysplasia.

Olivia de Jong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.